Medical device manufacturers navigating the post-Brexit regulatory landscape must understand three essential requirements for successful UK market access. First, independent registration is now mandatory for both Great Britain and Northern Ireland, with distinct procedural requirements for each jurisdiction under the Northern Ireland Protocol. Second, CE marking certification alone no longer provides automatic UK market access—manufacturers must pursue a separate MHRA registration pathway, fundamentally altering approval strategies for multinational companies.
Third, manufacturers should anticipate extended timelines when implementing dual compliance systems. The transition requires comprehensive documentation updates, device reclassification assessments, and submission procedures tailored to MHRA standards. Companies must allocate additional resources for parallel regulatory processes while maintaining existing EU compliance obligations. Understanding these practical implications enables manufacturers to develop realistic timelines for product launches and market expansion strategies in British territories.
Read the full article on GMJ Newsroom.
Was this article helpful?
